Search Results

Ben Myers!

GPCR Podcast, Ben, a postdoctoral fellow at the University of Michigan, walks us through how positive Redefining Opioid Pharmacology Ben and his colleagues discovered that PAMs can dramatically increase That’s huge.” – Ben Clements By combining chronic pain models with receptor-level pharmacology, Ben Ben’s approach injects new life into an area most clinicians have given up on. The GPCR Angle Ben sees GPCRs as untapped goldmines for drug discovery.

Ben Myers!

Ben Myers and Dr. Niña Caculitan.

January 2022 "Watch our CEO Tim Dyer on AlphaStreet. In his interview, Mr. Dyer provides an overview of our #allostericmodulator pipeline and the potential $4 billion market for

Ben Clements has been there. This simple advice, passed on to Ben in grad school, has helped him stay sane, focused, and impactful But as Ben points out, burnout is real, and it doesn’t make you better. Imposter Syndrome and Finding Your Place Ben shares the moment he realized he mattered, when he was : Try the Crazy Idea When a collaborator offered a neuroma model (one where opioids usually fail), Ben

Ben Clements has. And that moment, silly as it was, says a lot about how he sees science. Lab Culture Isn’t Just About Productivity Ben and his colleagues work hard in the lab. And we need that to do our best work.” – Ben Clements Mentorship Is the Engine of Science Ben chose When undergraduate students enter the lab, Ben doesn’t just teach them how to pipette, he teaches why

Ben Clements, a tour of our official Dr. Ben Clements   In Episode 166, Ben Clements dives into opioid pharmacology, GPCR-targeted PAMs, and how

tagging and interrogation of GPCR co-internalization Kilian Roßmann , Ramona Birke , Joshua Levitz , Ben

Applying Allosteric Modulator Pharmacology to Treat Dyskinesia and Other Movement Disorders with Tim Dyer Addex Therapeutics "Tim Dyer is the Co-Founder and CEO of Addex Therapeutics, which is focusing on the

This week's highlight includes congrats to: Madison Walker , Benjamin Myers , et al., for their research

Complexes Industry News Mavorixafor reduces infection rates among patients with WHIM syndrome Bristol Myers

Tim Dyer, CEO, Roger Mills, CMO and Robert Lütjens, Head of Discovery Biology, will provide a business

controls midgut development in Drosophila Karuna Therapeutics announces that is now part of Bristol Myers

3D was used to predict subtype-selective ligands for dopamine receptors and adenosine receptors (He, Ben

strategic priorities, including pursuing additional collaborations across our portfolio,” said Tim Dyer

Industry News Exscientia Announces First-in-Human Study for Bristol Myers Squibb In-Licensed PKC Theta

the present as prologue Industry News Exscientia Business Update for Third Quarter 2023 Addex CEO Tim Dyer

which have an established role in chemokine gradients and oligomerization (Deshauer C et al. 2015; Dyer

.; Iyer, M. R.; Cinar, R.; Coffey, N.

Rößler P, Mayer D, Tsai CJ, Veprintsev DB, Schertler GFX, Gossert AD.